check_circleStudy Completed
Breast Neoplasm
Bayer Identifier:
91466
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer
Trial purpose
The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) in patients with metastatic breast cancer helps to decrease or stop tumor growth.
Key Participants Requirements
Sex
FemaleAge
18 YearsTrial summary
Enrollment Goal
65Trial Dates
April 2006 - November 2008Phase
Phase 2Could I Receive a placebo
NoProducts
Sagopilone (BAY86-5302)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | M. D. Anderson Cancer Center - University of Texas | Houston, 77030, United States |
Completed | Cancer Care Center, Inc. | New Albany, 47150, United States |
Completed | University of Alabama at Birmingham | Birmingham, 35233, United States |
Completed | Georgetown University Medical Center | Washington, 20007, United States |
Completed | Genesis Cancer Center | Hot Springs, 71913, United States |
Completed | Hopital du St-Sacrement | Quebec, G1S 4L8, Canada |
Completed | Sir Mortimer B. Davis Jewish General Hospital | Montreal, H3T 1E2, Canada |
Completed | Greater Baltimore Medical Center | Baltimore, 21204, United States |
Terminated | Halifax Health Medical Center | Daytona Beach, 32114, United States |
Completed | Tacoma General Hospital | Tacoma, 98405, United States |
Completed | Comprehensive Blood and Cancer Center | Bakersfield, 93309, United States |
Completed | Comprehensive Cancer Center | Palm Springs, 92262, United States |
Completed | Weill Cornell Breast Center | New York, 10021, United States |
Completed | South Texas Oncology & Hematology, P.A. | San Antonio, 78207, United States |
Completed | Alaska Cancer Research and Education Center | Anchorage, 99508, United States |
Completed | Saint Barnabas Medical Center | Livingston, 07039, United States |
Completed | Oregon Health and Science University | Portland, 97239, United States |
Terminated | SUNY Upstate Medical University | Syracuse, 13210, United States |
Completed | University of Colorado Hospital | Aurora, 80010, United States |
Completed | Magee Womens Hospital of UPMC | Pittsburgh, 15213-3180, United States |
Completed | Sunnybrook Health Sciences Centre | Toronto, M4N 3M5, Canada |
Completed | University of Minnesota Physicians | Minneapolis, 55455, United States |
Terminated | Hopital Charles LeMoyne | Greenfield Park, J4V 2H1, Canada |
Terminated | University of Arizona Cancer Center | Tucson, 85724, United States |
Completed | Cancer Care Specialists of Central Illinois | Decatur, 62526, United States |
Primary Outcome
- Response to treatment with ZK-Epo after 6 cyclesdate_rangeTime Frame:complete or partial response after 2 to 6 courses of therapy.enhanced_encryptionnoSafety Issue:
Secondary Outcome
- Safety and tolerability of ZK-Epodate_rangeTime Frame:time to progression after start of study treatment and response duration from time between first date of confirmed PR or CR.enhanced_encryptionyesSafety Issue:
Trial design
Trial Type
InterventionalIntervention Type
DrugTrial Purpose
TreatmentAllocation
Non-randomizedBlinding
Open LabelAssignment
Single Group AssignmentTrial Arms
2